PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01144897|
Recruitment Status : Active, not recruiting
First Posted : June 16, 2010
Last Update Posted : May 15, 2018
|Condition or disease||Intervention/treatment||Phase|
|Castrate Resistant Prostate Cancer Prostate Cancer||Radiation: PET Acetate scan||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||5 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||PET Acetate for Docetaxel Response Assessment in Hormone-Refractory Prostate Cancer|
|Study Start Date :||June 2010|
|Actual Primary Completion Date :||November 2011|
|Estimated Study Completion Date :||October 2018|
Experimental: PET Acetate Imaging with Docetaxel
PET-acetate as an intermediate endpoint in the assessment of response of patients undergoing docetaxel for hormone refractory prostate cancer (HRPC).
Subjects will be treated with docetaxel, 75 mg/m2 every 21 days until disease progression or unacceptable toxicity occurs. Subjects will have two PET acetate scans - one prior to beginning chemotherapy and one approximately 8-9 weeks after chemotherapy has begun.
Radiation: PET Acetate scan
PET Acetate scans will be done to detect prostate cancer lesions.
- Interpretation of PET Acetate scans [ Time Frame: One year ]
- Prostate cancer response to treatment and progression (excluding PET Acetate assessment) [ Time Frame: 2-3 years ]Correlation with chemotherapy response.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01144897
|United States, Iowa|
|University of Iowa Hospitals and Clinics|
|Iowa City, Iowa, United States, 52242|
|Principal Investigator:||Daniel Vaena, MD||University of Iowa|